Analysts’ Weekly Ratings Updates for Johnson & Johnson (JNJ)

A number of firms have modified their ratings and price targets on shares of Johnson & Johnson (NYSE: JNJ) recently:

• 3/5/2026 – Johnson & Johnson had its price target raised by JPMorgan Chase & Co. from $225.00 to $250.00. They now have a “neutral” rating on the stock.
• 3/2/2026 – Johnson & Johnson had its “neutral” rating reaffirmed by Bank of America Corporation.
• 2/19/2026 – Johnson & Johnson had its price target raised by Rothschild & Co Redburn from $180.00 to $210.00. They now have a “neutral” rating on the stock.
• 2/14/2026 – Johnson & Johnson was downgraded by Wall Street Zen from “buy” to “hold”.
• 2/3/2026 – Johnson & Johnson had its price target raised by Royal Bank Of Canada from $240.00 to $255.00. They now have an “outperform” rating on the stock.
• 1/30/2026 – Johnson & Johnson had its price target raised by HSBC Holdings plc from $240.00 to $265.00. They now have a “buy” rating on the stock.
• 1/29/2026 – Johnson & Johnson had its price target raised by Daiwa Securities Group Inc. from $203.00 to $237.00. They now have an “outperform” rating on the stock.
• 1/28/2026 – Johnson & Johnson had its “buy (b)” rating reaffirmed by Weiss Ratings.
• 1/28/2026 – Johnson & Johnson was given a new $262.00 price target by Morgan Stanley. They now have an “overweight” rating on the stock.
• 1/27/2026 – Johnson & Johnson was given a new $220.00 price target by Loop Capital.
• 1/25/2026 – Johnson & Johnson was upgraded by Wall Street Zen from “hold” to “buy”.
• 1/23/2026 – Johnson & Johnson had its price target raised by Guggenheim from $227.00 to $240.00. They now have a “buy” rating on the stock.
• 1/23/2026 – Johnson & Johnson had its price target raised by Argus from $210.00 to $240.00.
• 1/23/2026 – Johnson & Johnson had its price target raised by Sanford C. Bernstein from $208.00 to $225.00. They now have a “market perform” rating on the stock.
• 1/22/2026 – Johnson & Johnson had its “outperform” rating reaffirmed by Scotiabank.
• 1/22/2026 – Johnson & Johnson had its price target raised by TD Cowen from $222.00 to $250.00. They now have a “buy” rating on the stock.
• 1/22/2026 – Johnson & Johnson had its price target raised by Morgan Stanley from $197.00 to $200.00. They now have an “equal weight” rating on the stock.
• 1/22/2026 – Johnson & Johnson had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $250.00 price target on the stock.
• 1/22/2026 – Johnson & Johnson had its price target raised by Citigroup Inc. from $232.00 to $250.00. They now have a “buy” rating on the stock.
• 1/22/2026 – Johnson & Johnson had its price target raised by Wells Fargo & Company from $230.00 to $240.00. They now have an “overweight” rating on the stock.
• 1/22/2026 – Johnson & Johnson had its price target raised by Leerink Partners from $201.00 to $232.00. They now have a “market perform” rating on the stock.
• 1/22/2026 – Johnson & Johnson had its price target raised by Bank of America Corporation from $220.00 to $221.00. They now have a “neutral” rating on the stock.
• 1/22/2026 – Johnson & Johnson had its price target raised by Scotiabank from $230.00 to $265.00. They now have a “sector outperform” rating on the stock.
• 1/22/2026 – Johnson & Johnson had its price target raised by Stifel Nicolaus from $205.00 to $220.00. They now have a “hold” rating on the stock.
• 1/17/2026 – Johnson & Johnson was downgraded by Wall Street Zen from “buy” to “hold”.
• 1/16/2026 – Johnson & Johnson was downgraded by Freedom Capital from “strong-buy” to “hold”.
• 1/9/2026 – Johnson & Johnson had its price target raised by Sanford C. Bernstein from $193.00 to $208.00. They now have a “market perform” rating on the stock.
• 1/5/2026 – Johnson & Johnson had its “buy” rating reaffirmed by UBS Group AG.
• 1/5/2026 – Johnson & Johnson had its price target raised by Wolfe Research from $225.00 to $240.00. They now have an “outperform” rating on the stock.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.2%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is 47.06%.

Insider Activity at Johnson & Johnson

In other news, EVP Vanessa Broadhurst sold 6,197 shares of the company’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the sale, the executive vice president directly owned 23,003 shares of the company’s stock, valued at $5,598,700.17. This represents a 21.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Timothy Schmid sold 1,322 shares of the firm’s stock in a transaction on Friday, February 20th. The stock was sold at an average price of $245.66, for a total transaction of $324,762.52. Following the transaction, the executive vice president directly owned 25,447 shares of the company’s stock, valued at approximately $6,251,310.02. This trade represents a 4.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 30,142 shares of company stock valued at $7,360,528. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.